Costs of tuberculosis disease in the European Union: a systematic analysis and cost calculation
Costs of tuberculosis disease in the European Union: a systematic analysis and cost calculation
复制标题
DOI：
10.1183/09031936.00079413
复制
发表时间：
2014-02-01
影响因子：
24.3
通讯作者：
Nienhaus, Albert
中科院分区：
文献类型：
--
作者：
Diel, Roland;Vandeputte, Joris;Nienhaus, Albert
如果没有更好的疫苗，结核病 (TB) 就不可能被消灭。欧盟 (EU) 认为开发一种新的有效疫苗需要大约 5.6 亿美元的投资。然而，人们对欧盟结核病的成本知之甚少。我们对涉及 27 个欧盟成员国的文献和机构网站进行了系统回顾，以总结成本数据。我们检索了 MEDLINE、EMBASE 和 Cochrane 参考书目以获取相关文章。结合直接和间接成本，我们得出了在最初的 EU-15 国家以及塞浦路斯、马耳他和斯洛文尼亚中，药物敏感结核病的平均每个结核病病例成本为 (原文如此)10 282，耐多药 (MDR) 结核病的平均每个结核病病例成本为 (原文如此)170 744，耐多药 (MDR) 结核病的平均成本为 (原文如此)170 744。耐药（XDR）-TB。在其余新欧盟国家，药物敏感结核病的费用为 (原文如此)3427，耐多药结核病/广泛耐药结核病的费用为 (原文如此)24 166。对于 70 340 例易感结核病病例，2011 年通报的 1488 例耐多药结核病和 136 例广泛耐药结核病病例，2012 年累计费用为 (原文如此)536 890 315。同年，这些病例造成的 103 104 伤残调整生命年，按货币计算，总计达 (原文如此)5 361 408 000. 因此，欧盟结核病造成的经济负担显然超过了投资更有效的结核病疫苗的成本。
Without better vaccines it is unlikely that tuberculosis (TB) will ever be eliminated. An investment of similar to(sic)560 million is considered necessary to develop a new, effective vaccine in the European Union (EU). However, less is known about the costs of TB disease in the EU. We performed a systematic review of literature and institutional websites addressing the 27 EU members to summarise cost data. We searched MEDLINE, EMBASE and Cochrane bibliographies for relevant articles.Combining direct and indirect costs, we arrived at an average per-TB case costs in the original EU-15 states plus Cyprus, Malta and Slovenia of (sic)10 282 for drug-susceptible TB, (sic)57 213 for multidrug resistant (MDR)-TB and (sic)170 744 for extensively drug resistant (XDR)-TB. In the remaining new EU states, costs amounted to (sic)3427 for drug-susceptible TB and (sic)24 166 for MDR-TB/XDR-TB. For the 70 340 susceptible TB cases, 1488 MDR-TB and 136 XDR-TB cases notified in 2011 costs of (sic)536 890 315 accumulated in 2012. In the same year, the 103 104 disability-adjusted life years caused by these cases, when stated in monetary terms, amounted to a total of (sic)5 361 408 000.Thus, the resulting economic burden of TB in the EU clearly outweighs the cost of investing in more efficient vaccines against TB.